The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Identifying patients at risk of severe inflammatory adverse events following ide-cel treatment
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the development of an inflammatory risk score to identify patients with multiple myeloma at risk of severe inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) treatment. The study identified that a cytokine signature associated with macrophage activity was associated with more severe adverse events. This score may be used to guide risk adapted management of CAR-T therapy and its related side effects.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
